Moreover, Wilson et al. showed that HGF promotes resistance to lapatinib in HER2-amplified breast cancers cells and to BRAF inhibitor in BRAF-mutated melanoma cells [163]. The gene discussed is ERBB2; the disease is breast carcinoma.